This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Most M&A Crazy Companies Since the Financial Crisis

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Johnson & Johnson (JNJ - Get Report)

In April, Johnson & Johnson bought medical device maker Synthes for $21.3 billion in the biggest merger in its 125 year history. The purchase added to a run of eight other crisis-time acquisitions over $250 million in size that's brought its deals total to $25.2 billion.

With Synthes, Johnson & Johnson took over a high quality maker of medical devices like screws and bone grafts, bolstering a health products unit that has recalled over 50 products since 2010, according to Bloomberg reports. Currently, J&J is the second largest maker of health products to Pfizer.

While J&J's underperformed its drug and medical products competitor, gaining just 5% year-to-date compared with Pfizer's 13% return, the company's shares are only down 10% from its pre-crisis highs in contrast to Pfizer's near 30% loss. Even after the deal, Moody's maintained J&J's AAA rating.

In total both Pfizer, with its $68 billion acquisition of Wyeth and Merck's (MRK - Get Report) $41 billion takeover of Schering-Plough in 2009 have cut larger deals than J&J, but neither has bought many other companies. In 2010, Merck ended an $8.2 billion animal health services joint venture with Sanofi Aventis (SNY) over complications to the deal like divestitures.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BAC $14.56 0.00%
BA $134.80 0.00%
BRK.B $145.48 0.00%
GE $30.75 0.00%
GS $164.11 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs